Immunic Inc (IMUX)
1.25
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
1.25
0.00 (0.00%)
After-Hours: 20:00
Immunic Net Income (Quarterly): -29.58M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -29.58M |
| December 31, 2023 | -21.57M |
| September 30, 2023 | -22.77M |
| June 30, 2023 | -24.00M |
| March 31, 2023 | -25.27M |
| December 31, 2022 | -56.47M |
| September 30, 2022 | -21.22M |
| June 30, 2022 | -21.90M |
| March 31, 2022 | -20.81M |
| December 31, 2021 | -21.18M |
| September 30, 2021 | -19.29M |
| June 30, 2021 | -17.93M |
| March 31, 2021 | -34.53M |
| December 31, 2020 | -11.16M |
| September 30, 2020 | -12.91M |
| June 30, 2020 | -11.46M |
| March 31, 2020 | -8.487M |
| December 31, 2019 | -7.691M |
| September 30, 2019 | -8.215M |
| June 30, 2019 | -14.71M |
| March 31, 2019 | -4.313M |
| December 31, 2018 | -2.464M |
| September 30, 2018 | -11.94M |
| June 30, 2018 | -12.68M |
| Date | Value |
|---|---|
| March 31, 2018 | -14.39M |
| December 31, 2017 | -14.59M |
| September 30, 2017 | -12.48M |
| June 30, 2017 | -12.41M |
| March 31, 2017 | -12.60M |
| December 31, 2016 | -11.73M |
| September 30, 2016 | -10.18M |
| June 30, 2016 | -9.468M |
| March 31, 2016 | -9.589M |
| December 31, 2015 | -9.859M |
| September 30, 2015 | -12.30M |
| June 30, 2015 | -15.11M |
| March 31, 2015 | -14.76M |
| December 31, 2014 | -13.96M |
| September 30, 2014 | -12.80M |
| June 30, 2014 | -10.17M |
| March 31, 2014 | -10.75M |
| December 31, 2013 | -10.24M |
| September 30, 2013 | -6.977M |
| June 30, 2013 | -6.144M |
| March 31, 2013 | -9.358M |
| December 31, 2012 | -0.394M |
| September 30, 2012 | -2.663M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-56.47M
Minimum
Dec 2022
-7.691M
Maximum
Dec 2019
-20.56M
Average
-21.00M
Median
Net Income (Quarterly) Benchmarks
| Kymera Therapeutics Inc | -48.56M |
| Insmed Inc | -157.09M |
| SELLAS Life Sciences Group Inc | -9.566M |
| Skye Bioscience Inc | -5.020M |
| Leap Therapeutics Inc | -13.82M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 23.88M |
| EPS Diluted (Quarterly) | -0.30 |
| Enterprise Value | 14.84M |
| Earnings Yield | -147.0% |